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Caution in the Use
of Bromocriptine in
Peripartum Cardiomyopathy
It is premature to attribute the recovery of 2 “postpartum cardio-
myopathy” patients to the blocking effect of bromocriptine against
prolactin and to assign causal relationship of 16 kDa prolactin to
human peripartum cardiomyopathy (PPCM) (1,2).
Both patients in heart failure were treated with angiotensin-
converting enzyme (ACE) inhibitor and beta-blocker drugs with
apparent benefit possibly even before the use of bromocriptine.
Most recent studies show that when PPCM is diagnosed in a
timely fashion and treatment is instituted with diuretic, ACE-
inhibitor, and beta-blocker drugs almost everyone improves, al-
most everyone survives, and over 50% completely recover left
ventricular systolic function (3,4). Furthermore, the rate of recov-
ery in many conventionally treated PPCM patients is often very
comparable to that seen in the 2 cases reported, without bro-
mocriptine in the picture.
I urge attention to the issue of the role of prolactin-suppression
with bromocriptine in the development of PPCM through care-
fully controlled, randomly assigned, double-blinded placebo stud-
ies, after addressing the following issues:
1) Is it safe to use bromocriptine in the early postpartum period?
A number of reports indicate acute myocardial infarction has
complicated the use of bromocriptine in healthy mothers for
lactate suppression (5). What will be the short-term and
long-term effects of circumventing the important natural
effects of prolactin on the involution process of the post-
gravida uterus?
2) Are the reputedly abnormal 16-kDa and the naturally occur-
ring 23-kDa derivatives of prolactin metabolism harmful?
Have sufficient studies been accomplished to be reasonably
confident that is the case?
3) Is serum prolactin significantly elevated in PPCM patients
either antepartum or post-partum as compared with healthy
non-PPCM patients? If so, as might be the case because of
efforts to stimulate lactation in an acutely or subacutely ill
mother, does that elevation constitute a causal relationship to
PPCM rather than a non-causal physiological response?
It is also important to pursue these issues, because if third world
mothers with PPCM—where the incidence is higher—were to
inhibit lactation through the use of bromocriptine or simply cease
breastfeeding in an effort to eventually decrease prolactin, many of
their newborns would die of malnutrition as a consequence of the
inability to provide a substitute for breast milk (6).
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Reply
We have not made the claim that our 2 cases would establish
bromocriptine as a treatment for peripartum cardiomyopathy
(PPCM), and 2 clinical cases never prove a novel concept. We
stated this clearly and mentioned that the efficacy of bromocriptine
in treating PPCM patients has to be evaluated in a controlled
randomized clinical trial (1). Thus, we agree with Dr. Fett’s point
that these 2 case reports are no proof for a beneficial effect of
bromocriptine in PPCM, even though meanwhile we have made
similar beneficial observations in 5 additional patients, applying
the same protocol.
Concerning the safety of bromocriptine, there are in fact several
case reports on myocardial infarction in early post-partum women
in association with taking bromocriptine (2). However, there is a
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naturally increased risk for thrombosis and myocardial infarction in
post-partum women (3). The risk for spontaneous coronary artery
dissection is also increased during pregnancy and in the post-
partum period independently from bromocriptine (4). Thus, there
are numerous reports on myocardial infarction in early post-
partum women independent of bromocriptine (5,6). Left ventric-
ular failure further increases the risk for thrombosis and infarction,
and anticoagulation therapy is strongly encouraged for these
reasons in PPCM patients. It should be noted that bromocriptine
has been used for more than 20 years successfully and safely to stop
lactation.
Dr. Fett raises the question of whether it is ethical in third
world countries to stop lactation in a woman with severe heart
failure, because this would increase the risk for the infant for
infection and malnutrition. Nursing is considered as an additional
stress factor for the mother’s heart. In addition, standard medica-
tion to treat heart failure (angiotensin-converting enzyme-
inhibitor, beta-blocker, and diuretic drugs) might be harmful for
the infant. Therefore, we would like to ask in return whether it is
ethical to expose women with severe heart failure due to PPCM
and their infants in a third world country to a higher risk for death
or disability because of nursing?
We should all aim to work together to find solutions and
hopefully efficient ways to treat this deadly disease and help
affected patients. Our goal is to establish as soon as possible
whether bromocriptine is efficient and safe to treat PPCM.
Professor Sliwa in South Africa has already started a controlled
randomized trial, and we are planning a trial in Europe and the
U.S. Dr. Fett would be in an ideal position in Haiti, with its high
incidence of PPCM, to take action!
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